Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
28 Febbraio 2024 - 2:00PM
Business Wire
– Company to host an Industry Forum to discuss
its approach to protecting and preserving dystrophic muscle
featuring key opinion leaders –
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle
disease biopharmaceutical company, today announced that the company
will present data on EDG-5506, an investigational therapy designed
to protect injury-susceptible fast skeletal muscle fibers in
dystrophinopathies, at the Muscular Dystrophy Association (MDA)
Clinical and Scientific Conference. The conference will take place
at the Hilton Orlando in Orlando, FL from March 3-6, 2024.
Details of the Edgewise presentations at MDA:
Podium Presentation in Clinical Trial
Updates Session
Title: Functional and Muscle Damage Biomarker Changes
Following Treatment with EDG-5506, a Fast Myosin Modulator, in
Adults with Becker Muscular Dystrophy
Dr. Phan’s presentation will include 12-month data from the ARCH
trial of EDG-5506.
Presenter: Han C. Phan, M.D., Head of Research &
Principal Investigator, Pediatric Neurologist, Rare Disease
Research, LLC
Date: Wednesday, March 6, 2024, 11:15 – 11:30 am ET
Scientific Posters
Title: Comparison of Short- and Long-Term Proteomic
Response to the Fast Skeletal Myosin Inhibitor, EDG-5506, in Becker
Muscular Dystrophy (BMD) (Poster # M145)
Title: North Star (NSAA and NSAD) Functional Assessments
in Individuals with Becker Muscular Dystrophy (poster # M147)
A companion poster presentation will be available for Dr. Phan’s
presentation (poster # M146). Posters will be showcased during the
Networking & Poster Reception in the Exhibit Hall on Monday,
March 4, 2024, from 6 – 8 PM ET. The full MDA 2024 Conference
program is available here: https://mdaconference.org.
The Edgewise presentation and posters will be available on the
Edgewise website when they are presented.
Edgewise Industry Forum with Key
Opinion Leaders
On March 4, 2024, at 12 pm ET, Edgewise is sponsoring an
Industry Forum, “Protecting and preserving dystrophic muscle: The
balance between exercise and contraction-induced muscle injury.”
The forum will feature presentations by leading neuromuscular
disease experts, John Vissing, M.D., Ph.D., Professor of Neurology,
Director Neuromuscular Clinic and Research Unit, Department of
Neurology, University of Copenhagen, and Tanja Taivassalo, Ph.D.,
Associate Professor, Department of Physiology and Aging, University
of Florida, as well as Edgewise Chief Medical Officer, Joanne
Donovan, M.D., Ph.D. Only registered conference attendees can
register for the symposium.
About EDG-5506 for Duchenne and Becker Muscular
Dystrophies
EDG-5506 is an orally administered small molecule designed to
prevent contraction-induced muscle damage in dystrophinopathies
including Duchenne and Becker. EDG-5506 presents a novel mechanism
of action designed to selectively limit the exaggerated muscle
damage caused by the absence or loss of functional dystrophin. By
minimizing the progressive muscle damage that leads to functional
impairment, EDG-5506 has the potential to benefit a broad range of
patients suffering from debilitating neuromuscular disorders. Its
unique mechanism of action provides the potential to establish
EDG-5506 as a foundational therapy in dystrophinopathies, either as
a single agent therapy or in combination with available therapies
and those in development. The Company is advancing EDG-5506 through
the clinic including completing enrollment of a Phase 2 trial
cohort, called CANYON, evaluating safety and effects on function
and biomarkers of muscle damage in adult males with Becker, which
has been expanded to include an additional 120 adult participants
in a pivotal cohort called GRAND CANYON, which is currently
enrolling. In Duchenne, the Company is advancing its Phase 2
clinical trials, LYNX, assessing safety, pharmacokinetics and
biomarkers of muscle damage, and FOX, which includes children and
adolescents previously treated with gene therapy. For more
information on Edgewise’s clinical trials
https://edgewisetx.com/clinical-trials.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease
biopharmaceutical company developing novel therapeutics for
muscular dystrophies and serious cardiac conditions. The Company’s
deep expertise in muscle physiology is driving a new generation of
first-in-class therapeutics. EDG-5506 is an orally administered
skeletal myosin inhibitor in clinical trials in patients with
Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as
McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel
cardiac sarcomere modulator for the treatment of HCM and other
disorders of cardiac diastolic dysfunction. The entire team at
Edgewise is dedicated to our mission: changing the lives of
patients and families affected by serious muscle diseases. To learn
more, go to: www.edgewisetx.com or follow us on LinkedIn, X
(formerly Twitter), Facebook, Instagram and Threads.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228531069/en/
Edgewise Contacts Investors: Michael Carruthers,
Chief Financial Officer ir@edgewisetx.com
Media: Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Edgewise Therapeutics (NASDAQ:EWTX)
Storico
Da Dic 2023 a Dic 2024
